Table 2. Estimates of grade 3/4 toxicity of neoadjuvant treatment including the 95% confidence interval from the random effect model and number of assessable studies for each group (n).

Group	Grade 3/4 Toxicity
All patients	29.4% [23.1%–36.1%]I2 = 91.3% [89.6%–92.7%](n = 63)
Tumor resectable before treatment (group 1)	26.3% [15.8%–38.3%]I2 = 92.8% [90.3%–94.6%](n = 22)
Tumor non-resectable before treatment (group 2)	31.1% [22.0%–40.9%]I2 = 91.6% [89.3%–93.5%](n = 33)